# SaNOtize Research and Development Corp.

> SaNOtize Research and Development Corp. is a Vancouver-based pharmaceutical and medical-device company that harnesses nitric oxide (NO), a naturally occurring antimicrobial molecule, to prevent and treat viral, bacterial and fungal infections. Its patented Nitric Oxide Releasing Solution (NORS) platform powers a Nitric Oxide Nasal Spray (NONS) sold internationally under brands including Enovid, VirX and FabiSpray, along with a pipeline addressing COVID-19, respiratory viruses, sinusitis, wound infection and onychomycosis.

- **Founded:** 2017
- **Headquarters:** Vancouver, British Columbia, Canada
- **Founders:** Gilly Regev (Co-Founder & CEO), Chris Miller (Co-Founder & Chief Scientific Officer)
- **Team size:** ~22 employees
- **Products:** Nitric Oxide Nasal Spray (NONS), Enovid, VirX, FabiSpray, NORS / NO Platform Technology
- **Notable:** Phase 3 clinical trial reported the nitric oxide nasal spray was highly effective at reducing SARS-CoV-2 viral load, leading to regulatory approval in India., Study in Bangkok, Thailand found participants using NONS after exposure were 75% less likely to become infected with COVID-19 versus control., Secured regulatory approvals/medical-device clearances across more than a dozen international markets.

## Products & services

- **Nitric Oxide Nasal Spray (NONS)** — Core product delivering nitric oxide to the nasal passage to reduce viral load and prevent infection; sold internationally under multiple brand names.
- **Enovid** — Brand name for NONS marketed in Israel, Indonesia, Bahrain and other markets as an antiviral nasal spray.
- **VirX** — Brand name for NONS sold as a medical device in markets including Thailand, Singapore, Hong Kong, Nepal, South Africa and Germany.
- **FabiSpray** — Prescription NONS commercialized in India through a licensing partnership with Glenmark Pharmaceuticals for COVID-19 treatment.
- **NORS / NO Platform Technology** — Patented Nitric Oxide Releasing Solution platform underpinning the company's antiviral, antibacterial and antifungal pipeline.
- **Nitric Oxide Releasing Gel (Onychomycosis)** — Topical nitric oxide-releasing gel demonstrating nail penetration and antifungal activity for nail fungus.
- **NONS for Sinusitis** — Phase 2 program evaluating the nasal spray for recurrent acute rhinosinusitis.

## Achievements

- Phase 3 clinical trial reported the nitric oxide nasal spray was highly effective at reducing SARS-CoV-2 viral load, leading to regulatory approval in India.
- Study in Bangkok, Thailand found participants using NONS after exposure were 75% less likely to become infected with COVID-19 versus control.
- Secured regulatory approvals/medical-device clearances across more than a dozen international markets.
- Raised an oversubscribed $24M Series B in 2022 amid a difficult funding climate.
- Expanded the platform beyond COVID-19 into sinusitis, wound infection and onychomycosis programs.

## Latest updates

- **2024-02** — Announced a Phase 2 trial evaluating the nitric oxide nasal spray for recurrent acute rhinosinusitis (sinusitis).
- **2024-01** — Published research on a novel nitric oxide-releasing topical gel showing nail penetration and antifungal activity for onychomycosis.
- **2022-08** — Closed a $24M Series B round co-led by Horizons Ventures and OurCrowd.

## Links

- Website: https://sanotize.com
- LinkedIn: https://www.linkedin.com/company/sanotize-research-and-development-corp
- Twitter/X: https://twitter.com/SanotizeD

---

Profile page: https://yespress.io/sanotize-research-and-development-corp
Published by YesPress — https://yespress.io
Last updated: 2026-07-18